http://hl7.org/fhir/uv/ebm/Composition/399872
type: Composition
node role: treeRoot
id:
  v: 399872
meta:
  version id:
    v: 5
  last updated:
    v: 2025-12-11T20:35:21.032Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/baseline-measure-report
    l: baseline-measure-report
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: Composition 399872 version: 5; Last updated: 2025-12-11 20:35:21+0000; Language: en Profile: BaselineMeasureReport url: https://fevir.net/resources/Composition/399872 identifier: FEvIR Object Identifier/399872, FEvIR Linking Identifier/NCT03421379-baseline-measure-report status: Final type: Baseline Measure Report date: 2025-12-11 20:35:21+0000 author: [No author listed.] title: Baseline Characteristics Report for NCT03421379 custodian: Computable Publishing LLC RelatesTos - Type Target[x] * Cite As Baseline Characteristics Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399872. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399872. Computable resource at: https://fevir.net/resources/Composition/399872#json. Generated Narrative: EvidenceVariable #NCT03421379-BaselineMeasure-0 Profile: VariableDefinition EvidenceVariableHandlingDetail: Evidence variable handling not specified title: Age, Continuous status: Active Definitions - Concept * Age, Continuous handling: evidence-variable-handling-not-specified classifier: Baseline Measure Timings - Offset[x] * No display for Duration (value: 0) Generated Narrative: EvidenceVariable #NCT03421379-BaselineMeasure-1 Profile: VariableDefinition EvidenceVariableHandlingDetail: Evidence variable handling not specified title: Sex: Female, Male status: Active Definitions - Concept * Sex: Female, Male handling: evidence-variable-handling-not-specified category name: Female category name: Male classifier: Baseline Measure Timings - Offset[x] * No display for Duration (value: 0) Generated Narrative: EvidenceVariable #NCT03421379-BaselineMeasure-2 Profile: VariableDefinition EvidenceVariableHandlingDetail: Evidence variable handling not specified title: Ethnicity (NIH/OMB) status: Active Definitions - Concept * Ethnicity (NIH/OMB) handling: evidence-va…
contained: EvidenceVariable
  id:
    v: NCT03421379-BaselineMeasure-0
  meta:
    profile:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition
      l: variable-definition
  extension:
    url:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-handling-detail
      l: evidence-variable-handling-detail
    value: CodeableConcept
  title:
    v: Age, Continuous
  status:
    v: active
  definition:
    concept:
      text:
        v: Age, Continuous
  handling:
    v: evidence-variable-handling-not-specified
  classifier:
    text:
      v: Baseline Measure
  timing:
    offset: Duration
      value:
        v: 0
contained: EvidenceVariable
  id:
    v: NCT03421379-BaselineMeasure-1
  meta:
    profile:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition
      l: variable-definition
  extension:
    url:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-handling-detail
      l: evidence-variable-handling-detail
    value: CodeableConcept
  title:
    v: Sex: Female, Male
  status:
    v: active
  definition:
    concept:
      text:
        v: Sex: Female, Male
  handling:
    v: evidence-variable-handling-not-specified
  category:
    name:
      v: Female
  category:
    name:
      v: Male
  classifier:
    text:
      v: Baseline Measure
  timing:
    offset: Duration
      value:
        v: 0
contained: EvidenceVariable
  id:
    v: NCT03421379-BaselineMeasure-2
  meta:
    profile:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition
      l: variable-definition
  extension:
    url:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-handling-detail
      l: evidence-variable-handling-detail
    value: CodeableConcept
  title:
    v: Ethnicity (NIH/OMB)
  status:
    v: active
  definition:
    concept:
      text:
        v: Ethnicity (NIH/OMB)
  handling:
    v: evidence-variable-handling-not-specified
  category:
    name:
      v: Hispanic or Latino
  category:
    name:
      v: Not Hispanic or Latino
  category:
    name:
      v: Unknown or Not Reported
  classifier:
    text:
      v: Baseline Measure
  timing:
    offset: Duration
      value:
        v: 0
contained: EvidenceVariable
  id:
    v: NCT03421379-BaselineMeasure-3
  meta:
    profile:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition
      l: variable-definition
  extension:
    url:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-handling-detail
      l: evidence-variable-handling-detail
    value: CodeableConcept
  title:
    v: Race (NIH/OMB)
  status:
    v: active
  definition:
    concept:
      text:
        v: Race (NIH/OMB)
  handling:
    v: evidence-variable-handling-not-specified
  category:
    name:
      v: American Indian or Alaska Native
  category:
    name:
      v: Asian
  category:
    name:
      v: Native Hawaiian or Other Pacific Islander
  category:
    name:
      v: Black or African American
  category:
    name:
      v: White
  category:
    name:
      v: More than one race
  category:
    name:
      v: Unknown or Not Reported
  classifier:
    text:
      v: Baseline Measure
  timing:
    offset: Duration
      value:
        v: 0
contained: EvidenceVariable
  id:
    v: NCT03421379-BaselineMeasure-4
  meta:
    profile:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition
      l: variable-definition
  extension:
    url:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-handling-detail
      l: evidence-variable-handling-detail
    value: CodeableConcept
  title:
    v: Region of Enrollment
  status:
    v: active
  definition:
    concept:
      text:
        v: Region of Enrollment
  handling:
    v: evidence-variable-handling-not-specified
  category:
    name:
      v: Japan
  classifier:
    text:
      v: Baseline Measure
  timing:
    offset: Duration
      value:
        v: 0
contained: Group
contained: Evidence

v: evidence-variable-handling-not-specified

v: Evidence variable handling not specified

v: evidence-variable-handling-not-specified

v: Evidence variable handling not specified

v: evidence-variable-handling-not-specified

v: Evidence variable handling not specified

v: evidence-variable-handling-not-specified

v: Evidence variable handling not specified

v: evidence-variable-handling-not-specified

v: Evidence variable handling not specified

Group
id:
  v: BG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group
    l: exposure-group
name:
  v: Glucagon Nasal Powder/Glucagon Hydrochloride Solution
description:
  v: A single dose of 3 mg glucagon nasal powder was administered intranasally
type:
  v: person
membership:
  v: enumerated
code:
  text:
    v: Participants
quantity:
  v: 33
characteristic:
  code:
    text:
      v: Research Study from which this is a baseline group
  value: Reference
    display:
      v: NCT03421379
  exclude:
    v: false

Group
id:
  v: BG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group
    l: exposure-group
name:
  v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
description:
  v: A single dose of 1 mg glucagon hydrochloride solution was administered IM
type:
  v: person
membership:
  v: enumerated
code:
  text:
    v: Participants
quantity:
  v: 39
characteristic:
  code:
    text:
      v: Research Study from which this is a baseline group
  value: Reference
    display:
      v: NCT03421379
  exclude:
    v: false

Group
id:
  v: BG002
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group
    l: exposure-group
name:
  v: Total
description:
  v: Total of all reporting groups
type:
  v: person
membership:
  v: enumerated
code:
  text:
    v: Participants
quantity:
  v: 72
characteristic:
  code:
    text:
      v: Research Study from which this is a baseline group
  value: Reference
    display:
      v: NCT03421379
  exclude:
    v: false

Evidence
id:
  v: NCT03421379-BaselineMeasure-0-BG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_0_BG000
title:
  v: Age, Continuous for Glucagon Nasal Powder/Glucagon Hydrochloride Solution at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG000
    reference:
      v: #BG000
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Nasal Powder/Glucagon Hydrochloride Solution
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-0
    reference:
      v: #NCT03421379-BaselineMeasure-0
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Age, Continuous
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000573
      display:
        v: mean
  quantity:
    value:
      v: 41.7
    unit:
      v: years
  sample size:
    known data count:
      v: 33
  attribute estimate:
    type:
      text:
        v: Standard Deviation
    quantity:
      value:
        v: 11.6
      unit:
        v: years

Evidence
id:
  v: NCT03421379-BaselineMeasure-0-BG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_0_BG001
title:
  v: Age, Continuous for Glucagon Hydrochloride Solution/Glucagon Nasal Powder at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG001
    reference:
      v: #BG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-0
    reference:
      v: #NCT03421379-BaselineMeasure-0
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Age, Continuous
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000573
      display:
        v: mean
  quantity:
    value:
      v: 57.5
    unit:
      v: years
  sample size:
    known data count:
      v: 39
  attribute estimate:
    type:
      text:
        v: Standard Deviation
    quantity:
      value:
        v: 9.2
      unit:
        v: years

Evidence
id:
  v: NCT03421379-BaselineMeasure-0-BG002
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_0_BG002
title:
  v: Age, Continuous for Total at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG002
    reference:
      v: #BG002
    type:
      v: Group
      l: Group
    display:
      v: Total
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-0
    reference:
      v: #NCT03421379-BaselineMeasure-0
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Age, Continuous
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000573
      display:
        v: mean
  quantity:
    value:
      v: 50.2
    unit:
      v: years
  sample size:
    known data count:
      v: 72
  attribute estimate:
    type:
      text:
        v: Standard Deviation
    quantity:
      value:
        v: 13
      unit:
        v: years

Evidence
id:
  v: NCT03421379-BaselineMeasure-1-BG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_1_BG000
title:
  v: Sex: Female, Male for Glucagon Nasal Powder/Glucagon Hydrochloride Solution at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG000
    reference:
      v: #BG000
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Nasal Powder/Glucagon Hydrochloride Solution
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-1
    reference:
      v: #NCT03421379-BaselineMeasure-1
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Sex: Female, Male
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Female
  quantity:
    value:
      v: 13
    unit:
      v: Participants
  sample size:
    known data count:
      v: 33
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Male
  quantity:
    value:
      v: 20
    unit:
      v: Participants
  sample size:
    known data count:
      v: 33

Evidence
id:
  v: NCT03421379-BaselineMeasure-1-BG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_1_BG001
title:
  v: Sex: Female, Male for Glucagon Hydrochloride Solution/Glucagon Nasal Powder at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG001
    reference:
      v: #BG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-1
    reference:
      v: #NCT03421379-BaselineMeasure-1
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Sex: Female, Male
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Female
  quantity:
    value:
      v: 9
    unit:
      v: Participants
  sample size:
    known data count:
      v: 39
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Male
  quantity:
    value:
      v: 30
    unit:
      v: Participants
  sample size:
    known data count:
      v: 39

Evidence
id:
  v: NCT03421379-BaselineMeasure-1-BG002
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_1_BG002
title:
  v: Sex: Female, Male for Total at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG002
    reference:
      v: #BG002
    type:
      v: Group
      l: Group
    display:
      v: Total
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-1
    reference:
      v: #NCT03421379-BaselineMeasure-1
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Sex: Female, Male
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Female
  quantity:
    value:
      v: 22
    unit:
      v: Participants
  sample size:
    known data count:
      v: 72
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Male
  quantity:
    value:
      v: 50
    unit:
      v: Participants
  sample size:
    known data count:
      v: 72

Evidence
id:
  v: NCT03421379-BaselineMeasure-2-BG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_2_BG000
title:
  v: Ethnicity (NIH/OMB) for Glucagon Nasal Powder/Glucagon Hydrochloride Solution at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG000
    reference:
      v: #BG000
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Nasal Powder/Glucagon Hydrochloride Solution
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-2
    reference:
      v: #NCT03421379-BaselineMeasure-2
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Ethnicity (NIH/OMB)
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Hispanic or Latino
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 33
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Not Hispanic or Latino
  quantity:
    value:
      v: 33
    unit:
      v: Participants
  sample size:
    known data count:
      v: 33
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Unknown or Not Reported
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 33

Evidence
id:
  v: NCT03421379-BaselineMeasure-2-BG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_2_BG001
title:
  v: Ethnicity (NIH/OMB) for Glucagon Hydrochloride Solution/Glucagon Nasal Powder at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG001
    reference:
      v: #BG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-2
    reference:
      v: #NCT03421379-BaselineMeasure-2
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Ethnicity (NIH/OMB)
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Hispanic or Latino
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 39
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Not Hispanic or Latino
  quantity:
    value:
      v: 39
    unit:
      v: Participants
  sample size:
    known data count:
      v: 39
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Unknown or Not Reported
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 39

Evidence
id:
  v: NCT03421379-BaselineMeasure-2-BG002
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_2_BG002
title:
  v: Ethnicity (NIH/OMB) for Total at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG002
    reference:
      v: #BG002
    type:
      v: Group
      l: Group
    display:
      v: Total
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-2
    reference:
      v: #NCT03421379-BaselineMeasure-2
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Ethnicity (NIH/OMB)
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Hispanic or Latino
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 72
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Not Hispanic or Latino
  quantity:
    value:
      v: 72
    unit:
      v: Participants
  sample size:
    known data count:
      v: 72
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Unknown or Not Reported
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 72

Evidence
id:
  v: NCT03421379-BaselineMeasure-3-BG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_3_BG000
title:
  v: Race (NIH/OMB) for Glucagon Nasal Powder/Glucagon Hydrochloride Solution at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG000
    reference:
      v: #BG000
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Nasal Powder/Glucagon Hydrochloride Solution
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-3
    reference:
      v: #NCT03421379-BaselineMeasure-3
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Race (NIH/OMB)
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: American Indian or Alaska Native
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 33
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Asian
  quantity:
    value:
      v: 33
    unit:
      v: Participants
  sample size:
    known data count:
      v: 33
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Native Hawaiian or Other Pacific Islander
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 33
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Black or African American
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 33
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: White
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 33
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: More than one race
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 33
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Unknown or Not Reported
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 33

Evidence
id:
  v: NCT03421379-BaselineMeasure-3-BG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_3_BG001
title:
  v: Race (NIH/OMB) for Glucagon Hydrochloride Solution/Glucagon Nasal Powder at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG001
    reference:
      v: #BG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-3
    reference:
      v: #NCT03421379-BaselineMeasure-3
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Race (NIH/OMB)
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: American Indian or Alaska Native
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 39
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Asian
  quantity:
    value:
      v: 39
    unit:
      v: Participants
  sample size:
    known data count:
      v: 39
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Native Hawaiian or Other Pacific Islander
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 39
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Black or African American
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 39
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: White
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 39
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: More than one race
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 39
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Unknown or Not Reported
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 39

Evidence
id:
  v: NCT03421379-BaselineMeasure-3-BG002
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_3_BG002
title:
  v: Race (NIH/OMB) for Total at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG002
    reference:
      v: #BG002
    type:
      v: Group
      l: Group
    display:
      v: Total
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-3
    reference:
      v: #NCT03421379-BaselineMeasure-3
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Race (NIH/OMB)
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: American Indian or Alaska Native
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 72
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Asian
  quantity:
    value:
      v: 72
    unit:
      v: Participants
  sample size:
    known data count:
      v: 72
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Native Hawaiian or Other Pacific Islander
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 72
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Black or African American
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 72
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: White
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 72
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: More than one race
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 72
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: count
    text:
      v: Count of Participants
  category:
    text:
      v: Unknown or Not Reported
  quantity:
    value:
      v: 0
    unit:
      v: Participants
  sample size:
    known data count:
      v: 72

Evidence
id:
  v: NCT03421379-BaselineMeasure-4-BG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_4_BG000
title:
  v: Region of Enrollment for Glucagon Nasal Powder/Glucagon Hydrochloride Solution at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG000
    reference:
      v: #BG000
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Nasal Powder/Glucagon Hydrochloride Solution
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-4
    reference:
      v: #NCT03421379-BaselineMeasure-4
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Region of Enrollment
statistic:
  statistic type:
    text:
      v: Number (see protocol for details)
  category:
    text:
      v: Japan
  quantity:
    value:
      v: 33
    unit:
      v: participants
  sample size:
    known data count:
      v: 33

Evidence
id:
  v: NCT03421379-BaselineMeasure-4-BG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_4_BG001
title:
  v: Region of Enrollment for Glucagon Hydrochloride Solution/Glucagon Nasal Powder at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG001
    reference:
      v: #BG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-4
    reference:
      v: #NCT03421379-BaselineMeasure-4
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Region of Enrollment
statistic:
  statistic type:
    text:
      v: Number (see protocol for details)
  category:
    text:
      v: Japan
  quantity:
    value:
      v: 39
    unit:
      v: participants
  sample size:
    known data count:
      v: 39

Evidence
id:
  v: NCT03421379-BaselineMeasure-4-BG002
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence
    l: non-comparative-evidence
name:
  v: NCT03421379_BaselineMeasure_4_BG002
title:
  v: Region of Enrollment for Total at baseline in NCT03421379
status:
  v: active
variable definition:
  note:
    text:
      v: Baseline Reporting Population Description: All randomized participants who received at least one dose of study drug.
  variable role:
    v: population
  observed:
    l: BG002
    reference:
      v: #BG002
    type:
      v: Group
      l: Group
    display:
      v: Total
variable definition:
  variable role:
    v: outcome
  observed:
    l: NCT03421379-BaselineMeasure-4
    reference:
      v: #NCT03421379-BaselineMeasure-4
    type:
      v: EvidenceVariable
      l: EvidenceVariable
    display:
      v: Region of Enrollment
statistic:
  statistic type:
    text:
      v: Number (see protocol for details)
  category:
    text:
      v: Japan
  quantity:
    value:
      v: 72
    unit:
      v: participants
  sample size:
    known data count:
      v: 72

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v2-0203
      l: v2-0203
    code:
      v: ACSN
    display:
      v: Accession ID
  text:
    v: FEvIR Object Identifier
system:
  v: https://fevir.net/FOI
  l: FOI
value:
  v: 399872
assigner:
  display:
    v: Computable Publishing LLC

type:
  text:
    v: FEvIR Linking Identifier
system:
  v: https://fevir.net/FLI
  l: FLI
value:
  v: NCT03421379-baseline-measure-report
assigner:
  display:
    v: Computable Publishing LLC

v: final

coding:
  system:
    v: https://fevir.net/resources/CodeSystem/179423
    l: https://fevir.net/resources/CodeSystem/179423
  code:
    v: BaselineMeasureReport
  display:
    v: BaselineMeasureReport
text:
  v: Baseline Measure Report

v: 2025-12-11T20:35:21.032Z

display:
  v: [No author listed.]

v: Baseline Characteristics Report for NCT03421379

l: http://hl7.org/fhir/uv/ebm/Organization/118079
reference:
  v: Organization/118079
type:
  v: Organization
  l: Organization
display:
  v: Computable Publishing LLC

type:
  v: cite-as
target: Markdown
  v: Baseline Characteristics Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399872. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399872. Computable resource at: https://fevir.net/resources/Composition/399872#json.

title:
  v: Baseline Reporting Population Description
code:
  text:
    v: BaselinePopulationDescription
text:
  status:
    v: generated
  div:
    v: All randomized participants who received at least one dose of study drug.

title:
  v: Baseline Group List
code:
  text:
    v: BaselineGroupList
text:
  status:
    v: generated
  div:
    v: Glucagon Nasal Powder/Glucagon Hydrochloride Solution, Glucagon Hydrochloride Solution/Glucagon Nasal Powder, Total
entry:
  l: BG000
  reference:
    v: #BG000
  type:
    v: Group
    l: Group
  display:
    v: Glucagon Nasal Powder/Glucagon Hydrochloride Solution
entry:
  l: BG001
  reference:
    v: #BG001
  type:
    v: Group
    l: Group
  display:
    v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
entry:
  l: BG002
  reference:
    v: #BG002
  type:
    v: Group
    l: Group
  display:
    v: Total

title:
  v: Age, Continuous
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
focus:
  l: NCT03421379-BaselineMeasure-0
  reference:
    v: #NCT03421379-BaselineMeasure-0
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  display:
    v: Age, Continuous
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-BaselineMeasure-0-BG000
  reference:
    v: #NCT03421379-BaselineMeasure-0-BG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: Age, Continuous for Glucagon Nasal Powder/Glucagon Hydrochloride Solution at baseline in NCT03421379
entry:
  l: NCT03421379-BaselineMeasure-0-BG001
  reference:
    v: #NCT03421379-BaselineMeasure-0-BG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: Age, Continuous for Glucagon Hydrochloride Solution/Glucagon Nasal Powder at baseline in NCT03421379
entry:
  l: NCT03421379-BaselineMeasure-0-BG002
  reference:
    v: #NCT03421379-BaselineMeasure-0-BG002
  type:
    v: Evidence
    l: Evidence
  display:
    v: Age, Continuous for Total at baseline in NCT03421379

title:
  v: Sex: Female, Male
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
focus:
  l: NCT03421379-BaselineMeasure-1
  reference:
    v: #NCT03421379-BaselineMeasure-1
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  display:
    v: Sex: Female, Male
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-BaselineMeasure-1-BG000
  reference:
    v: #NCT03421379-BaselineMeasure-1-BG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: Sex: Female, Male for Glucagon Nasal Powder/Glucagon Hydrochloride Solution at baseline in NCT03421379
entry:
  l: NCT03421379-BaselineMeasure-1-BG001
  reference:
    v: #NCT03421379-BaselineMeasure-1-BG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: Sex: Female, Male for Glucagon Hydrochloride Solution/Glucagon Nasal Powder at baseline in NCT03421379
entry:
  l: NCT03421379-BaselineMeasure-1-BG002
  reference:
    v: #NCT03421379-BaselineMeasure-1-BG002
  type:
    v: Evidence
    l: Evidence
  display:
    v: Sex: Female, Male for Total at baseline in NCT03421379
section:
  title:
    v: Baseline Measure Calculate Percent
  code:
    text:
      v: BaselineMeasureCalculatePct
  text:
    status:
      v: generated
    div:
      v: False

title:
  v: Ethnicity (NIH/OMB)
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
focus:
  l: NCT03421379-BaselineMeasure-2
  reference:
    v: #NCT03421379-BaselineMeasure-2
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  display:
    v: Ethnicity (NIH/OMB)
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-BaselineMeasure-2-BG000
  reference:
    v: #NCT03421379-BaselineMeasure-2-BG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: Ethnicity (NIH/OMB) for Glucagon Nasal Powder/Glucagon Hydrochloride Solution at baseline in NCT03421379
entry:
  l: NCT03421379-BaselineMeasure-2-BG001
  reference:
    v: #NCT03421379-BaselineMeasure-2-BG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: Ethnicity (NIH/OMB) for Glucagon Hydrochloride Solution/Glucagon Nasal Powder at baseline in NCT03421379
entry:
  l: NCT03421379-BaselineMeasure-2-BG002
  reference:
    v: #NCT03421379-BaselineMeasure-2-BG002
  type:
    v: Evidence
    l: Evidence
  display:
    v: Ethnicity (NIH/OMB) for Total at baseline in NCT03421379
section:
  title:
    v: Baseline Measure Calculate Percent
  code:
    text:
      v: BaselineMeasureCalculatePct
  text:
    status:
      v: generated
    div:
      v: False

title:
  v: Race (NIH/OMB)
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
focus:
  l: NCT03421379-BaselineMeasure-3
  reference:
    v: #NCT03421379-BaselineMeasure-3
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  display:
    v: Race (NIH/OMB)
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-BaselineMeasure-3-BG000
  reference:
    v: #NCT03421379-BaselineMeasure-3-BG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: Race (NIH/OMB) for Glucagon Nasal Powder/Glucagon Hydrochloride Solution at baseline in NCT03421379
entry:
  l: NCT03421379-BaselineMeasure-3-BG001
  reference:
    v: #NCT03421379-BaselineMeasure-3-BG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: Race (NIH/OMB) for Glucagon Hydrochloride Solution/Glucagon Nasal Powder at baseline in NCT03421379
entry:
  l: NCT03421379-BaselineMeasure-3-BG002
  reference:
    v: #NCT03421379-BaselineMeasure-3-BG002
  type:
    v: Evidence
    l: Evidence
  display:
    v: Race (NIH/OMB) for Total at baseline in NCT03421379
section:
  title:
    v: Baseline Measure Calculate Percent
  code:
    text:
      v: BaselineMeasureCalculatePct
  text:
    status:
      v: generated
    div:
      v: False

title:
  v: Region of Enrollment
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
focus:
  l: NCT03421379-BaselineMeasure-4
  reference:
    v: #NCT03421379-BaselineMeasure-4
  type:
    v: EvidenceVariable
    l: EvidenceVariable
  display:
    v: Region of Enrollment
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-BaselineMeasure-4-BG000
  reference:
    v: #NCT03421379-BaselineMeasure-4-BG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: Region of Enrollment for Glucagon Nasal Powder/Glucagon Hydrochloride Solution at baseline in NCT03421379
entry:
  l: NCT03421379-BaselineMeasure-4-BG001
  reference:
    v: #NCT03421379-BaselineMeasure-4-BG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: Region of Enrollment for Glucagon Hydrochloride Solution/Glucagon Nasal Powder at baseline in NCT03421379
entry:
  l: NCT03421379-BaselineMeasure-4-BG002
  reference:
    v: #NCT03421379-BaselineMeasure-4-BG002
  type:
    v: Evidence
    l: Evidence
  display:
    v: Region of Enrollment for Total at baseline in NCT03421379